7 research outputs found

    Influence of (-)-α-pinene on EtBr accumulation in the 16 <i>C</i>. <i>jejuni</i> strains.

    No full text
    <p>Relationship between EtBr accumulation in untreated cultures and in cultures treated with 62.5 mg/L (-)-α-pinene. Each symbol represents a single isolate. Solid squares, antibiotic resistant strains (resistant to three or more unrelated antibiotics); open circles, antibiotic sensitive strains.</p

    Scheme of the insertional mutagenesis strategies (not to scale).

    No full text
    <p>Box arrows, target open reading frames; solid arrows, primers used for DNA fragment amplification (from left to right: F1-F, F1-R, F2-F, F2-R, specific for each individual mutant, as listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122871#pone.0122871.s002" target="_blank">S2 Table</a>); blue dots, target gene; blue rectangles, deleted regions substituted with a kanamycin cassette (<i>kan</i>).</p

    Influence of (-)-α-pinene, CCCP and reserpine on ethidium bromide accumulation.

    No full text
    <p>(A) Reference strain <i>C</i>. <i>jejuni</i> NCTC 11168, (B) <i>C</i>. <i>jejuni</i> NCTC 11168 ΔcmeB knock-out mutant, (C) <i>C</i>. <i>jejuni</i> NCTC 11168 Δ<i>Cj1687</i> knock-out mutant.</p

    Antimicrobial activity and modulation of antimicrobial resistance of (-)-α-pinene for the different strains of <i>Campylobacter jejuni</i>.

    No full text
    <p>MIC, minimal inhibitory concentration; AP, (-)-α-pinene; CIP, ciprofloxacin; ERY: erythromycin; TC, triclosan; EtBr, ethidium bromide;-AP, in the absence of (-)-α-pinene; +AP, with 125 mg/L (-)-α-pinene, MF, modulation factor.</p><p>* In this case +AP was applied in concentration 62.5 mg/L.</p><p>Antimicrobial activity and modulation of antimicrobial resistance of (-)-α-pinene for the different strains of <i>Campylobacter jejuni</i>.</p

    Influence of (-)-α-pinene on membrane integrity of <i>C</i>. <i>jejuni</i> NCTC 11168.

    No full text
    <p>Membrane integrity of wild-type <i>C</i>. <i>jejuni</i> NCTC 11168 cultures, untreated culture, culture treated with 125 mg/L (-)-α-pinene or 62.5 mg/L (-)-α-pinene, heat treated culture and blank.</p

    Discovery of Core-Fucosylated Glycopeptides as Diagnostic Biomarkers for Early HCC in Patients with NASH Cirrhosis Using LC-HCD-PRM-MS/MS

    No full text
    Aberrant changes in site-specific core fucosylation (CF) of serum proteins contribute to cancer development and progression, which enables them as potential diagnostic markers of tumors. An optimized data-dependent acquisition (DDA) workflow involving isobaric tags for relative and absolute quantitation-labeling and enrichment of CF peptides by lens culinaris lectin was applied to identify CF of serum proteins in a test set of patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis (N = 16) and hepatocellular carcinoma (HCC, N = 17), respectively. A total of 624 CF peptides from 343 proteins, with 683 CF sites, were identified in our DDA–mass spectrometry (MS) analysis. Subsequently, 19 candidate CF peptide markers were evaluated by a target parallel reaction-monitoring–MS workflow in a validation set of 58 patients, including NASH-related cirrhosis (N = 29), early-stage HCC (N = 21), and late-stage HCC (N = 8). Significant changes (p < 0.01) were observed in four CF peptides between cirrhosis and HCC, where peptide LGSFEGLVn160LTFIHLQHNR from LUM in combination with AFP showed the best diagnostic performance in discriminating HCC from cirrhosis, with an area under curve (AUC) of 0.855 compared to AFP only (AUC = 0.717). This peptide in combination with AFP also significantly improved diagnostic performance in distinguishing early HCC from cirrhosis, with an AUC of 0.839 compared to AFP only (AUC = 0.689). Validation of this novel promising biomarker panel in larger cohorts should be performed
    corecore